News

NICHD has appointed Daniel S. Johnston, Ph.D., as Chief of its Contraception Research Branch.

Researchers funded by the National Institutes of Health have discovered the cellular switch that boosts the activity of sperm cells so that they can travel to the egg. The finding may lead to new options for male contraception as well as treatments for infertility resulting from problems with sperm mobility.

Obese young women may be less likely to use birth control than their normal-weight peers, placing them at greater risk for unintended pregnancy, according to researchers funded by the National Institutes of Health.

NICHD’s Population Dynamics Branch supports research on a range of topics, including the factors that make populations rise and fall, such as fertility and mortality. We checked in with branch chief Rebecca Clark to learn more about the branch’s work.

Birth control pills are less effective for obese women. Studies have shown that obesity brings with it hormonal changes that can reduce the pill’s effectiveness.

During June—Men’s Health Month—the NICHD focused on encouraging men to make their health a priority.

Contraception allows couples to prevent pregnancy or better control the timing of when they conceive. The NICHD’s Contraceptive Discovery and Development Branch (CDDB) supports research on new contraceptive methods, for women and for men, to meet the diverse needs of individuals throughout their reproductive lives.

On average, men die about five years earlier than women and have higher mortality rates from some cancers and heart disease, according to the Centers for Disease Control and Prevention (CDC). It’s important, then, that men talk to their health care providers about what types of preventive medical tests and activities they need to stay healthy.

Lisa M. Halvorson, M.D., has been named the new Chief of the Gynecologic Health and Disease Branch (GHDB), effective June 15, 2014, announced Dr. Catherine Spong, M.D., Director of the Division of Extramural Research.

On December 5, 2012, the NICHD released the Scientific Vision: The Next Decade, the culmination of a collaborative process that began in 2011 to identify the most promising scientific opportunities for the Institute and the research community to pursue over the next decade. The Vision statement was made available during the NICHD’s 50th anniversary colloquium.

​Alan Guttmacher, M.D., Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) announced a number of changes to streamline the institute’s organizational structure and accelerate the exchange of scientific ideas.

A document charting a research course for the many collaborators who share an interest in promoting the science concerning human development through the life span, child health, women's health, and rehabilitation research is now available online.

As the Institute marks its golden anniversary, we look back on the NICHD's early years, its scientific accomplishments, and its future.

NICHD Director Alan E. Guttmacher, M.D., initiated the NICHD Director’s Lecture Series as a way to showcase cutting-edge science relevant to the Institute’s mission. The forum also enables staff and other attendees to interact with other nationally recognized scientists.

Using hormonal contraception does not appear to increase women's overall risk of infection with the AIDS virus, report the authors of a large study commissioned by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health.

Lower bone density appears to recover in adolescent females once they stop using the injected contraceptive depot medroxyprogesterone acetate (DMPA), according to a study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health.

A team of researchers has determined that an enzyme in sperm is necessary for sperm movement. Mice bred to lack this enzyme produce sperm that cannot swim toward egg cells to fertilize them.

The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman's risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three fold when compared to women not using a hormonal contraceptive, according to a study jointly funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health and the U.S. Agency for International Development's Office of Population and Reproductive Health.

A new study confirms earlier reports that Depo-Provera, an injectable contraceptive popular among young and low-income American women, is strongly associated with bone density loss.

Women between the ages of 35 and 64 who took oral contraceptives at some point in their lives are no more likely to develop breast cancer than are other women the same age, according to findings from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Women's Contraceptive and Reproductive Experiences Study (Women's CARE).